Use of dutasteride in carcinoma prostate

Summary This is a multi-centric randomized, placebo controlled trial with 294 patients with a rising prostate specific antigen (PSA), following radical radiotherapy (RT), radical prostatectomy (RP) with or without salvage radiotherapy, or primary radiotherapy alone for clinically localized prostate...

Full description

Saved in:
Bibliographic Details
Published in:Indian journal of urology 2014-01, Vol.30 (1), p.123-124
Main Author: Shrinivas, R
Format: Article
Language:English
Subjects:
Diagnosis
Drug therapy
Dutasteride
Health aspects
Medical research
Prostate cancer
Prostate-specific antigen
Radiation therapy
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary This is a multi-centric randomized, placebo controlled trial with 294 patients with a rising prostate specific antigen (PSA), following radical radiotherapy (RT), radical prostatectomy (RP) with or without salvage radiotherapy, or primary radiotherapy alone for clinically localized prostate carcinoma (PCa) with curative intent, being randomized 1:1 between placebo and dutasteride 0.5 mg once daily for 2 year. Another significant finding noted was the lower incidence of disease progression in the dutasteride group (17%; 25 of 146) compared with the placebo (34%; 49 of 144) in terms of incidence of PSA related progression like PSADT < 3 mo, Absolute high PSA and clinical progression such as positive biopsy, bone metastasis and the need for rescue therapy like anti-androgens or luteinizing hormone-releasing hormone therapy.
ISSN:0970-1591
1998-3824